Heteroalicyclic derivatives and their use in the treatment of CNS disorders
Heteroalicyclic piperazine and piperidine derivatives address the limitations of current antipsychotics by functioning as multi-receptor antagonists, effectively treating CNS disorders with reduced side effects and improved safety.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-01-11
- Publication Date
- 2026-03-11
AI Technical Summary
Current antipsychotic medications for CNS disorders like schizophrenia and bipolar disorder have significant side effects such as involuntary movement disorders, cognitive slowing, and increased mortality in elderly patients with dementia, necessitating the development of novel compounds with improved therapeutic selectivity and safety profiles.
Development of heteroalicyclic substituted piperazine and piperidine derivatives that act as dopamine D2, 5-HT1A, and 5-HT2A receptor antagonists, and serotonin reuptake inhibitors, reducing the risk of side effects like extrapyramidal symptoms and tardive dyskinesia.
The compounds demonstrate efficacy in animal models of schizophrenia and related disorders, attenuating cognitive deficits while minimizing side effects, offering a safer treatment option for CNS disorders.
Smart Images

Figure 0007828459000072 
Figure 0007828459000073 
Figure 0007828459000074
Abstract
Citation Information
Patent Citations
Piperazine (piperidine) cyclohexyl derivative and applications of piperazine (piperidine) cyclohexyl derivative in treatment of neuropsychiatric diseases
CN105367565A
Novel 2,9-disubstituted-4H-pyrido-[1,2-a]pyrimidin-4-ones
EP0453042A1
Imide derivatives, and their production and use
EP0464846A1
3-piperadinyl benzoazole derivative having antipsychotic activity
JP1990088572A
New 2,9-disubstituted-4h-pyrido(1,2-a)pyrimidin-4- one
JP1992234882A